The effect of chronic hexarelin administration on the pituitary–adrenal axis and prolactin

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Clinical Endocrinology

• Publication date

  1999-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-2265.1999.00609.xPMID 10341859
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Growth hormone status during long-term hexarelin therapy.

  1998cited by this paper
• Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.

  1998cited by this paper
• Oestrogen replacement does not restore the reduced GH-releasing activity of Hexarelin, a synthetic hexapeptide, in post-menopausal women.

  1997cited by this paper
• Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging.

  1996cited by this paper
• Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.

  1996cited by this paper
• Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study.

  1996cited by this paper
• Growth hormone treatment in hypopituitary GH deficient adults reduces circulating cortisol levels during hydrocortisone replacement therapy

  1996cited by this paper
• Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man.

  1995influential reference
• The effect of an opiate antagonist on the hormonal changes induced by hexarelin

  1995influential reference
• Differential effects of insulin and insulin-like growth factor I on the production of plasma steroid-binding globulins by human hepatoblastoma-derived (Hep G2) cells.

  1995influential reference
• Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin)

  1994cited by this paper
• Growth hormone-releasing activity of hexarelin in humans

  1994cited by this paper
• The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults

  1994cited by this paper
• Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.

  1994influential reference
• Growth hormone-releasing activity of growth hormone-releasing peptide-1 (a synthetic heptapeptide) in children and adolescents.

  1993cited by this paper
• Quantitation of urinary hydroxypyridinium cross-links from collagen by high-performance liquid chromatography.

  1992cited by this paper
• Intranasal administration of His-D-Trp-Ala-Trp-D-Phe-LysNH2 (growth hormone releasing peptide) increased plasma growth hormone and insulin-like growth factor-I levels in normal men.

  1991cited by this paper
• Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.

  1990cited by this paper
• Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects.

  1989influential reference
• On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.

  1984cited by this paper
• Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Adrenocorticotropin- and Cortisol-Releasing Effect of Hexarelin, a Synthetic Growth Hormone-Releasing

  year unknowncited by this paper

• Ameliorative Effect of Ghrelin on Thyroxin Hormones and Body Weight in Hyperthyroidism Male rats

  2021cites this paper
• Birth anthropometry and cord blood leptin in Korean appropriate-for-gestational-age infants born at ≥ 28 weeks’ gestation: a cross sectional study

  2020cites this paper
• Reproductive performance and fertility in male and female adult mice chronically treated with hexarelin.

  2012cites this paper
• Diagnostic criteria and clinico-epidemiological features of thyroid storm based on a nationwide survey

  2012cites this paper
• Ghrelin and glucose homeostasis.

  2011cites this paper
• Integrating GHS into the Ghrelin System

  2010influential citation
• Ghrelin affects the hypothalamus-pituitary-thyroid axis in humans by increasing free thyroxine and decreasing TSH in plasma.

  2010cites this paper
• by increasing free thyroxine (fT4) and decreasing TSH in plasma

  2010cites this paper
• Diagnosis of Adrenal Insufficiency Using the GHRP-6 Test: Comparison with the Insulin Tolerance Test in Patients with Hypothalamic-Pituitary-Adrenal Disease

  2009cites this paper
• Diagnosis of Growth Hormone Deficiency in Adults: Provocative Testing with GHRP6 in Comparison to the Insulin Tolerance Test

  2008cites this paper
• Glucocorticoid-dependent stimulation of adiposity and appetite by a ghrelin mimetic in the rat.

  2004cites this paper
• Non-Growth Hormone Endocrine Actions of Ghrelin

  2004cites this paper
• Ghrelin--a hormone with multiple functions.

  2004cites this paper
• Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.

  2004cites this paper
• GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing’s disease: Comparison with DDAVP

  2003cites this paper
• Effects of plasmid-mediated growth hormone releasing hormone supplementation in young, healthy Beagle dogs.

  2003cites this paper
• Prolactin-releasing activity of GHRP-5 (Momany peptide) on lactotrophs in vivo and in vitro.

  2002cites this paper
• Ghrelin and synthetic GH secretagogues.

  2002cites this paper
• Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.

  2002cites this paper
• Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans.

  2001cites this paper
• Skeletal Growth Acceleration with Growth Hormone Secretagogues in Transgenic Growth Retarded Rats: Pattern‐Dependent Effects and Mechanisms of Desensitization

  2001cites this paper
• Growth hormone releasing peptides: physiology and clinical applications

  2000cites this paper
• Glucocorticoid regulation of growth hormone (GH) secretagogue-induced growth responses and GH secretagogue receptor expression in the rat.

  2000cites this paper
• The effects of dose, nutrition, and age on hexarelin-induced anterior pituitary hormone secretion in adult patients on maintenance hemodialysis.

  1999cites this paper